Antibiotic Resistance and the Cost to Healthcare Systems
The economic burden of antibiotic resistance is staggering. Resistant infections lead to longer hospital stays, costlier treatments, and higher mortality rates. Countries worldwide are spending billions to combat infections that were once easy to cure.
The dental sector is not immune to this challenge. Oral infections, especially post-surgical ones, are increasingly difficult to treat when bacteria no longer respond to standard antibiotics. In cases where dental implants or bone grafts are involved, infection can compromise outcomes entirely. This makes advancements in the Dental Bone Graft Substitutes Market highly relevant—not just for structural repair, but also for minimizing infection risk.
Governments are now focusing on antibiotic stewardship programs to optimize use in both human and veterinary medicine. At the same time, pharmaceutical research is leaning into alternative therapies, like bacteriophages and antimicrobial peptides.
Ultimately, controlling antibiotic resistance isn’t just about new drugs—it’s about ensuring that existing treatments remain effective. This means doctors, dentists, and patients alike need to rethink how they approach antibiotics in daily care.